zonisamide (Zonegran)

From Aaushi
Jump to navigation Jump to search

Introduction

Tradename: Zonegran.

Indications

Contraindications

Dosage

25-100 mg QD

Take with copious fluids to reduce risk of nephrolithiasis

* dosage adjustment in liver failure uncertain[6]

Dosage adjustment in renal failure

Pharmacokinetics

elimination via liver

Monitor

Adverse effects

Drug interactions

  • any drug that inhibits cyt P450 3A4 may increase levels of zonisamide
  • any drug that induces cyt P450 3A4 may diminish levels of zonisamide

Laboratory

More general terms

Additional terms

References

  1. Prescriber's Letter 7(5):28, May 2000
  2. 2.0 2.1 2.2 2.3 2.4 Prescriber's Letter 13(3): 2006 Cytochrome P450 drug interactions Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=220233&pb=PRL (subscription needed) http://www.prescribersletter.com
  3. Prescriber's Letter 10(6):32 2003
  4. Murata M, Hasegawa K, Kanazawa I; The Japan Zonisamide on PD Study Group. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology. 2007 Jan 2;68(1):45-50. PMID: https://www.ncbi.nlm.nih.gov/pubmed/17200492
  5. 5.0 5.1 FDA Medwatch http://www.fda.gov/medwatch/safety/2009/safety09.htm#Zonisamide
  6. 6.00 6.01 6.02 6.03 6.04 6.05 6.06 6.07 6.08 6.09 6.10 6.11 6.12 Medical Knowledge Self Assessment Program (MKSAP) 15, 16, 17, 18. American College of Physicians, Philadelphia 2009, 2012, 2015, 2018.
  7. 7.0 7.1 7.2 Prescriber's Letter 17(7): 2010 Recommended Lab Monitoring for Common Medications Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=260704&pb=PRL (subscription needed) http://www.prescribersletter.com
  8. 8.0 8.1 8.2 Wandschneider B et al. Effect of topiramate and zonisamide on fMRI cognitive networks. Neurology 2017 Feb 17 PMID: https://www.ncbi.nlm.nih.gov/pubmed/28213372
  9. 9.0 9.1 9.2 9.3 Murata M, Odawara T, Hasegawa K et al. Adjunct zonisamide to levodopa for DLB parkinsonism: A randomized, double-blind phase 2 study. Neurology 2018 Jan 24 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29367449 Free PMC Article <Internet> http://n.neurology.org/content/90/8/e664

Database